GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guangdong Hybribio Biotech Co Ltd (SZSE:300639) » Definitions » Return-on-Tangible-Equity

Guangdong Hybribio Biotech Co (SZSE:300639) Return-on-Tangible-Equity : -1.26% (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Guangdong Hybribio Biotech Co Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Guangdong Hybribio Biotech Co's annualized net income for the quarter that ended in Mar. 2024 was ¥-57.4 Mil. Guangdong Hybribio Biotech Co's average shareholder tangible equity for the quarter that ended in Mar. 2024 was ¥4,563.1 Mil. Therefore, Guangdong Hybribio Biotech Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -1.26%.

The historical rank and industry rank for Guangdong Hybribio Biotech Co's Return-on-Tangible-Equity or its related term are showing as below:

SZSE:300639' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 1.32   Med: 18.55   Max: 44.5
Current: 1.32

During the past 12 years, Guangdong Hybribio Biotech Co's highest Return-on-Tangible-Equity was 44.50%. The lowest was 1.32%. And the median was 18.55%.

SZSE:300639's Return-on-Tangible-Equity is ranked better than
53.03% of 198 companies
in the Medical Diagnostics & Research industry
Industry Median: -0.72 vs SZSE:300639: 1.32

Guangdong Hybribio Biotech Co Return-on-Tangible-Equity Historical Data

The historical data trend for Guangdong Hybribio Biotech Co's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guangdong Hybribio Biotech Co Return-on-Tangible-Equity Chart

Guangdong Hybribio Biotech Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.40 22.33 31.91 44.50 3.03

Guangdong Hybribio Biotech Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.59 4.97 4.29 -2.75 -1.26

Competitive Comparison of Guangdong Hybribio Biotech Co's Return-on-Tangible-Equity

For the Diagnostics & Research subindustry, Guangdong Hybribio Biotech Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guangdong Hybribio Biotech Co's Return-on-Tangible-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guangdong Hybribio Biotech Co's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Guangdong Hybribio Biotech Co's Return-on-Tangible-Equity falls into.



Guangdong Hybribio Biotech Co Return-on-Tangible-Equity Calculation

Guangdong Hybribio Biotech Co's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=140.472/( (4688.39+4584.476 )/ 2 )
=140.472/4636.433
=3.03 %

Guangdong Hybribio Biotech Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-57.42/( (4584.476+4541.715)/ 2 )
=-57.42/4563.0955
=-1.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Guangdong Hybribio Biotech Co  (SZSE:300639) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Guangdong Hybribio Biotech Co Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Guangdong Hybribio Biotech Co's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Guangdong Hybribio Biotech Co (SZSE:300639) Business Description

Traded in Other Exchanges
N/A
Address
D 5-3-3-4, North High-tech Zone, Economic Development Zone, Chaozhou City, CHN, 521000
Guangdong Hybribio Biotech Co Ltd is a Chinese company engaged in offering vitro diagnostic assays. Its products include in-vitro diagnostic kits, female sample collection kit, DNA extraction kit, and other devices. The company's products help in the infectious pathogens detection and genetic disease detection, including human papillomavirus, thalassemia, G6PD, hearing loss susceptibility, phenylketonuria, and early cancer detection, among others. The company has a business presence in China and various other countries.

Guangdong Hybribio Biotech Co (SZSE:300639) Headlines

No Headlines